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pancreatic (pro)enzymes treatment 
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María Ángel García2,3,5,6, Carlos chocarro-Wrona2,3,4,6, Juan Antonio Marchal  2,3,4,6, 
Julian Kenyon7 & Macarena perán  1,6
cancer stem cells (cScs) subpopulation within the tumour is responsible for metastasis and cancer 
relapse. Here we investigate in vitro and in vivo the effects of a pancreatic (pro)enzyme mixture 
composed of chymotrypsinogen and trypsinogen (pRp) on cScs derived from a human pancreatic 
cell line, BxPC3. Exposure of pancreatic CSCs spheres to PRP resulted in a significant decrease of 
ALDEFLUOR and specific pancreatic CSC markers (CD 326, CD 44 and CxCR4) signal tested by flow 
cytometry, further CSCs markers expression was also analyzed by western and immunofluorescence 
assays. pRp also inhibits primary and secondary sphere formation. three Rt2 Profiler PCR Arrays 
were used to study gene expression regulation after PRP treatment and resulted in, (i) epithelial-
mesenchymal transition (EMT) inhibition; (ii) CSCs related genes suppression; (iii) enhanced expression 
of tumour suppressor genes; (iv) downregulation of migration and metastasis genes and (v) regulation 
of MAP Kinase Signalling Pathway. Finally, in vivo anti-tumor xenograft studies demonstrated high 
anti-tumour efficacy of PRP against tumours induced by BxPC3 human pancreatic CSCs. PRP impaired 
engrafting of pancreatic CSC’s tumours in nude mice and displayed an antigrowth effect toward 
initiated xenografts. We concluded that (pro)enzymes treatment is a valuable strategy to suppress the 
cSc population in solid pancreatic tumours.
Improving therapies against hematopoietic malignancies and solid tumours are making cancer a chronic disease 
and represent a short-term success. Nevertheless, among cancers, pancreatic ductal adenocarcinoma still has a 
very poor prognosis with short life expectancy. To decrease cancer mortality rate, strategies to prevent cancer 
recurrence are needed.
The discovery of a subpopulation of cells with stem cell-like features, called cancer stem cells (CSCs), in a wide 
spectrum of solid tumours1 has led to a new model of tumorigenesis, the CSCs hypothesis. This model suggests 
that the intrinsic characteristics of these cells, such as self-renewal and the ability to differentiate, drive tumour 
initiation and progression, and the subsequent chance of developing metastasis and tumour recurrence2. The 
CSCs hypothesis is based on the following findings: (i) CSCs represent a small fraction of cancer cells within 
a tumour; CSCs have tumorigenic potential when transplanted into immunodeficient mice; (ii) CSCs can be 
isolated by specific surface markers; (iii) tumours resulting from the CSCs contain mixed tumorigenic and 
non-tumorigenic cells of the original tumour; and (iv) CSCs can be serially transplanted through multiple gen-
erations, indicating that it is a self-renewing population3,4. An additional and very important feature of the CSCs 
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population is their ability to remain quiescent for extended periods of time, and therefore evade conventional 
therapies (chemo- and radiotherapy) that are targeted to highly proliferative cells5. Consequently, a priority for 
improving cancer treatment and reducing the risk of cancer relapse is to develop new strategies that selectively 
target CSC eradication while sparing normal stem cells.
One of the biggest challenges in CSCs research has been the development of methods for culture, expansion, 
and analyses of undifferentiated cancer cells in vitro. In this respect, our group has experience in CSCs enrich-
ment from cancer cell lines or from cancer cells isolated from patients. We have recently patented a method to 
isolate and culture CSCs and we have also implemented different studies to test drugs directed against CSCs6.
Previous research has suggested a putative utility of pancreatic (pro)enzymes in cancer treatment7,8. In agree-
ment with these studies, we have shown in vivo and in vitro the anti-tumour efficacy of a novel pro-enzyme 
formulation consisting of a combination of Trypsinogen and Chymotrypsinogen A (PRP), that proves to be an 
effective and non-toxic treatment, able to induce lineage specific cellular differentiation, inhibit angiogenesis, 
tumour growth, cancer cell migration and invasiveness. Furthermore, a suppository formulation containing both 
pancreatic pro-enzymes increased the life expectancy of advanced cancer patients9,10. Based on these findings, we 
postulated that pancreatic pro-enzymes may induce differentiation of CSCs and reduce recurrence and metastatic 
spread. Here we have tested, in vitro and in vivo, the effect of the formulation PRP on CSCs isolated from the 
human pancreatic cancer cell line BxPC3. To do so, we first determined the effect of the anti-cancer drug on cell 
viability, proliferation and sphere formation capacity of CSCs isolated from BxPC3. Second, we analysed changes 
in pancreatic CSCs markers after treatment. Third, we have analysed with RT2 Profiler PCR Arrays changes of 
expression of genes involved in EMT or related to CSCs and MAP Kinase Signalling Pathway induced by PRP 
treatment. Four, we have studied expression of mirRNAs related to CSCs and to characterize the mechanism of 
action of the pro-enzyme formulation we have studied protein expression. Finally, we have conducted a xenograft 
study to assess the effect of PRP in suppressing tumour growth in vivo.
We can conclude that PRP reduces the CSC population, tumour initiation and decreases fibrotic tissue in 
tumours.
Results
pRp treatment reduces cScs population in pancreatic cancer. We have previously described the 
anti-tumor effect of PRP in some pancreatic, colon, oesophagus and ovarian cancer cell lines9,10. To test the selec-
tive action of PRP against pancreatic CSCs enriched subpopulations we first determined the IC50 by MTT assay 
(Fig. 1A). ALDH has been described as a marker for the identification of CSCs11. Here we detected ALDH posi-
tive cells by ALDEFLUOR assay using flow cytometry (Fig. 1B) and proved that treatment with PRP significantly 
reduces the population of ALDH positive cells (from 47.2% to 17.5%) in pancreatic CSCs. Furthermore, Fig. 1B 
shows that the percentage of cells that express specific pancreatic CSCs markers CD 44, CD 326 and CxCR4 
significantly decreased after PRP treatment from 75.1% to 9.5%; from 51.2% to 5.5% and from 63.1% to 42.4% 
respectively, which signifies that PRP treatment reduces CSCs population in pancreatic cancer cells. Finally, we 
further determine the expression of the pancreatic cancer markers CD44, CD326 and CxCR4 by immunofluores-
cence (Fig. 1C) and by western blotting (Fig. 1D and Supplementary Fig. S1). Both assays demonstrate that PRP 
reduced the expression of specific pancreatic CSCs markers by a decrease in fluorescence red signal shown by 
treated cells when compared with control cells, which was corroborated by western blotting analysis.
pRp inhibits spheroid formation by cScs. We next tested if PRP could suppress sphere formation by 
pancreatic CSCs. To do so, PRP, was added to the medium at day 0, on cancer cells cultured under sphere condi-
tions (conditioned medium and low attached culture wells) and compared with the effect of gemcitabine, one of 
the main chemotherapy drugs used to treat pancreatic cancer. Figure 1E shows images of cell cultures on day 2 
and day 3. On day 2 it is clear that the addition of PRP to the medium significantly reduces the number and size 
of CSC spheres. In addition, the morphology of the spheres formed is markedly different, being regular in the 
control non-treated cells while it was quite irregular in PRP treated cells. On day 3, PRP treated cells do not form 
spheres and showed the appearance of non-healthy disaggregated cells. BXPC-3 primary spheres treated with 
PRP demonstrated inhibition of proliferation significantly different from the control group and similar to gemcit-
abine treatment. The combination treatment of PRP and gemcitabine resulted in a statistically significant decrease 
in primary CSCs compared to both PRP treatment alone (p < 0.01) and gemcitabine treatment alone (p < 0.01) 
(Fig. 1F). Moreover, PRP abolished secondary sphere-formation (Fig. 1E) an effect comparable to treatment with 
gemcitabine. There were statistically significant differences between formed secondary spheres when cells were 
treated with PRP or gemcitabine alone compared with the control group and between the PRP/gemcitabine com-
bined treatment and all other experimental groups (p < 0.01). The highest rate of secondary sphere inhibition was 
observed in the group treated with PRP and gemcitabine (p < 0.01) (Fig. 1F).
PRP treatment induces genome-wide gene expression changes in pancreatic CSCs. To under-
stand the molecular changes underlying PRP exposure to pancreatic CSCs, we performed three PCR microar-
ray analysis to measure regulation of the EMT process, CSCs characteristics and variations in Kinase Signalling 
Pathway related to the treatment. Figure 2A shows up regulation of selective genes that are down regulated during 
the EMT process. It is important to note that E-cadherin displayed a fold regulation of 4.3, indicating that PRP 
treatment clearly induces its expression. Furthermore, Kruppel-like-factor 17 (KLF17) a negative regulator of 
metastasis and EMT12 was also up-regulated by PRP treatment, reaching a fold regulation of 5.9. Other genes 
such as MST1R (1.6 folds); TFPI2 (4.4 folds) and NUDT13 (2.3 folds), significantly increased their expression 
after pro-enzyme treatment, implying potent anti-EMT effects of the PRP formulation. Genes that are up regu-
lated during EMT were analysed and the results are summarized in Fig. 2B. Remarkably, 13 genes that have been 
described to induce EMT were down regulated with PRP treatment. Of interest, the transcription factor Snail 
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Figure 1. In vitro analysis of tumorigenic capacity of BXPC3 CSCs after PRP treatment. (A) Antiproliferative 
activity of PRP against CSCs from pancreatic BXPC3 cell line. (B) Decreased ALDH1 activity and CSCs 
markers expression: CD44, CD326 and CXCR4 in BXPC3 CSCs. (C) Representative confocal images of CD44, 
CxCR-4 and CD326 expression in BxPC3 treated and control CSCs. CD44, CD326 and CxCR-4 expression 
were detected in red and nuclei were counterstained with DAPI (blue). Scale bar represents 40 μm. (D) Western 
blot analysis of CD44, CD326 and CxCR-4 in BXPC3 CSCs treated with PRP versus non-treated. Β-actin and 
GAPDH were used as a internal controls. (E) Representative images of BXPC-3 primary and secondary spheres 
treated with PRP (T/C 0.07/0.42 mg/mL) at 48 and 72 hours after treatment. Scale bar represents 50 μm. (F) 
In vitro proliferation assay on BXPC-3 CSCs after treatment with PRP and gemcitabine. BXPC-3 primary 
and secondary spheres were incubated with PRP, gemcitabine (0,01 μM treatment) or with a combination of 
PRP/gemcitabine 72 h. The PRP, gemcitabine and combination of PRP and gemcitabine treatment resulted 
in a statistically significant decrease in primary and secondary CSCs spheres compared to control. Statistical 
significance indicated **p < 0.01. vs. samples not treated.
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which is up-regulated in metastatic cells that are undergoing EMT, was down regulated (SNAI1: −1.9 folds and 
SNAI2: −1.86 folds). In addition, the serine protease inhibitor SERPINE1, a poor prognostic biomarker in various 
cancers that promotes tumour progression13, presented a noticeable fold down regulation of −4.6. Furthermore, 
gene expression of the integrins ITGA5 (−2.5 folds) and ITGAV (−1.02 folds) were also down regulated.
In previous studies, we proved that PRP induces cell differentiation in the pancreatic cancer cell line Panc19. 
Here, 7 genes related to cell differentiation were up-regulated after PRP treatment (Fig. 2C). Also, the expres-
sion of epidermal growth factor (EGF), related to beta cell differentation14, increased 8.9 folds when compared 
with control cells. Furthermore, pro-enzyme treatment of pancreatic CSCs induced down-regulation of 6 genes 
recognized as CSCs markers (Fig. 1D). Although we found a high up-regulation of Nanog (23 folds), interest-
ingly other genes directly involved in the maintenance or acquisition of stemness such as Oct4 and KLF4 were 
down-regulated due to PRP addition. In addition, the specific CSCs markers CD38, CD45, CD24 and CD34 were 
down regulated (−12.8 folds; −6.7 folds; −1.4 folds and −1.2 folds respectively); while CD133 was up-regulated 
(3.9 folds) (Fig. 2D).
Figure 3A shows that 8 genes implicated in metastasis and cell invasion were down-regulated by PRP treat-
ment (PLAUR; BMP7; DKK1; ITGB1; PLAT; FN1; PDGFRB and SPP1) Furthermore, the expression of seven 
genes related to cell adhesion were up-regulated (Fig. 3B). It is important to note that the expression of E-cadherin 
(4.3 folds) and β-catenin (4 folds) was enhanced by pro-enzyme treatment in agreement with our previous stud-
ies9. In addition, 11 genes with a tumour suppressor role were up-regulated by pro-enzyme treatment, results 
are summarized in Fig. 3C. Remarkably there was enhanced expression of the transcription factor FOXP1 (6.04 
Figure 2. Gene expression profiling of BxPC3 CSCs treated with PRP using RNA Human EMT and CSCs 
RT2 Profiler PCR Array. BxPC3 CSCs were treated with PRP on day 2 and on day 4. On day 5, total RNA from 
treated and non-treated CSCs was extracted. A pool of three total RNAs extracted from three independent 
experiments was used for first strand cDNA synthesis. Gene expression was determined using RT2 Profiler PCR 
Array of EMT and CSCs. (A) Expression of genes up regulated during EMT. (B) Expression of genes down 
regulated during EMT. (C) Expression of genes related to differentiation and development. (D) Expression of 
genes related to CSCs. All gene expressions were normalised to the untreated control.
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folds), TWIST2 (5.2 folds) and THY1 (3.622 folds). In addition, SPARC, an extracellular protein involved in the 
deposition and modelling of the extracellular matrix that is downregulated in many tumour types was found to be 
up-regulated (3.6 folds) by PRP treatment. Furthermore, SIRT1, a member of the sirtuin family of proteins proven 
to inhibit proliferation of pancreatic cancer cells15, increased the expression in 2 folds in treated cells.
The expression of genes encoding cytokines was investigated after PRP treatment and compared with 
untreated pancreatic CSCs. Figure 3D shows down-regulation of IKBKB; IL8; PECAM1; IL1RN and SPP1. 
Remarkably, IL-8 (−4.5 folds) and Secreted phosphoprotein-1 (SPP1, −10 folds).
Finally, the Human MAP Kinase Signaling Pathway RT2 Profiler PCR Array was used to profile the expression 
of 84 genes related to the MAP kinase (MAPK) signalling pathway. As can be observed in Fig. 4A,B, genes related 
to JNK and ERK pathways are down-regulated as a consequence of PRP treatment, for instance relevant onco-
genic transcription factors JUN (−7 folds), FOS (−7.3 folds) and MEK1 (MAP2K1) (−4.7 folds). Furthermore, 
PRP induced the up-regulation of cyclin-dependent kinase inhibitor genes (CDKN2A, 3.9 folds; CDKN2B, 2 
folds and CDKN2C, 3.8 folds) and decreased the expression of DLK1 (−8.5 folds). In addition, SFN-1 (YWHAZ) 
gene was down regulated by PRP treatment (−5.2 folds). Moreover, we found p16; SMAD4 and TP53 to be 
up-regulated Fig. 4A.
Figure 4B summarizes in an in-silico analysis the relationship between some of the genes that were 
downregulated after PRP treatment, which are involved in the TGFβ SMAD-independent pathway, such as 
Figure 3. Human EMT and CSCs RT2 Profiler PCR Array of BxPC3 CSCs treated with PRP. BxPC3 CSCs were 
treated with PRP on day 2 and on day 4. On day 5, total RNA from treated and non-treated CSCs was extracted. 
A pool of three total RNAs extracted from three independent experiments was used for first strand cDNA 
synthesis. Gene expression was determined using RT2 Profiler PCR Array of EMT and CSCs. (A) Expression 
of genes genes related to metastasis. (B) Expression of genes related to cell adhesion. (C) Expression of tumour 
suppresor genes. (D) Expression of genes related to cytokines. All gene expressions were normalised to the 
untreated control.
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mitogen-activated protein kinases (MAPKs) including c-Jun N-terminal kinase (JNK), p38, and extracellular 
signal-regulated kinase (ERK) (reviewed by Solomon, 2014)16.
The expression levels of other genes in the microPCR panels did not significantly change after PRP treatment 
as is shown in Supplementary Fig S2.
Q-PCR analyssis of Rac1, Rac1b and Smad7 gene expression in pancreatic CSCs treated with 
pRp. Since Rac1 is a key mediator of EMT in pancreatic cancer, and it has been shown that the Rac1-related 
isoform, Rac1b, acts as an endogenous inhibitor of Rac1 in TGFβ signalling, we analyzed Rac1b and Rac1 + Rac1b 
expression in PRP treated cells by RTqPCR. As demonstrated in Fig. 5A, Rac1 + Rac1b and Rac1b gene expres-
sion were significantly up-regulated following PRP treatment (2.1-fold and 3.4-fold respectively, p < 0.01) indi-
cating that (pro)enzymes treatment may favours decreased expression of TGFβ1-induced tumorigenic events, 
including EMT, invasion, and metastasis.
In addition the expression of Smad7 (Fig. 5A) was significantly downregulated after PRP treatment (approx-
imately 1 fold).
PRP treatment change miRNA expression. To further explore the effect of PRP formulation on pancre-
atic CSCs, we analysed known pancreatic cancer miRNAs. Interestingly, we observed that miR-21-5p and miR-
182-3p levels were significantly down-regulated after pancreatic CSCs were treated with PRP (Fig. 5B) (p < 0.01). 
In addition, results showed that treated CSCs increased expression of miRNA-7 (Fig. 5B) (p < 0.05).
pRp treatment downregulates both Smad-dependent and Smad-independent pathways in 
tGfβ signaling. To support the claim that PRP regulates TGFβ pathway the expression of phosphorylated 
Figure 4. Screening of MAP Kinase Signalling Pathway genes by RT2 Profiler PCR Array. (A) BxPC3 CSCs 
were treated with PRP on day 2 and on day 4. On day 5, total RNA from treated and non-treated CSCs were 
extracted. A pool of three total RNAs extracted from three independent experiments was used for first strand 
cDNA synthesis. Gene expression was determined using MAP Kinase Signalling Pathway RT2 Profiler PCR 
Array. Sixteen genes were up-regulated, whereas twelve were downregulated compared to the controls. (B) 
Functional in-silico analysis of proteins related to the c-Jun N-terminal kinase (JNK) pathway. Grey lines 
represent protein-protein associations, line thickness indicates the strength of data support (active interaction 
sources from experimental and database only). Red circles highlights genes coding for those proteins that were 
downregulated by PRP treatment.
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Figure 5. PRP treatment downregulated both Smad-dependent and Smad-independent pathways in TGFβ 
signaling. (A) RT-qPCR analysis of Rac1b; Rac1 + Rac1b and Smad 7 after PRP treatment. All gene expressions 
were normalised to the untreated control. (B) RT-qPCR analysis show the fold change of miR-21-5p, miR-
182-3p and miRNA-7. Values were normalized using the UniSp6 RNA Spike-in control primer set. (C) Treated 
and not treated BxPC3 CSCs were incubated with TGFβ1 (5 ng/mL) for 2 h, 4 h and 10 h. The phosphorylation 
levels of Smad2/3 and total Smad2/3 were analyzed by western blotting at indicated time points. (D) The relative 
expression of p-Smad2/3 and total Smad2/3 normalized to β-Actin was quantified using Image-J software 
NIH and is shown as a ratio of p-Smad2/3 versus Smad2/3. (E) Western blotting analysis of p-p38 and total 
p38 expression in CSCs treated with PRP versus non-treated. The relative expression of p-p38 and total p38 
normalized to GAPDH was quantified using Image-J software NIH and is shown as a ratio p-p38/p38 Different 
letters stand for significant differences (p < 0.05).
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Smad2/3 was detected under TGFβ stimulation with time intervals in control and treated cells (Fig. 5C, 
Supplementary Figs S3 and 4 and Fig. 5D). Stimulation of control cells with TGFβ led to an increment of 
p-Smad2/3 that has a peak at 2 hours of TGFβ induction. On the other hand, cells treated with PRP did not show 
a significant increment in p-Smad2/3 after TGFβ stimulation in any of the time intervals tested (Fig. 5C,D).
We next studied the effect of PRP on the Smad-independent branch of TGFβ pathway by analyzing the phos-
phorylation of p38 after PRP treatment. Figure 5E (Supplementary Fig. S5) shows that the amount of phophoy-
ilated p38 significantly decreased after treatment when compared with control cells.
Thus, PRP seams to act throught TGF-β patway, the inhibition of Smad2/3 and p38 phosphorylation may 
implay that these proteins will not be translocated into the nucleus to regulate multiple EMT-relevant transcrip-
tion factors as is shown below.
pRp inhibit eMt by directly enhancing e-cadherin and β-catenin expression. We performed 
immunological analyses to detect the expression of the cell adhesion markers β-catenin and E-cadherin. Our 
results show that non-treated CSCs displayed distinct membrane localization of β-catenin and weak, diffuse 
nuclear and cytoplasmic staining while PRP treated CSCs maintain membrane-associated and cytoplasmic stain-
ing of β-catenin without nuclear translocation (Fig. 6A). Treated cells maintained E-cadherin expression despite 
the PRP treatment destroyed the spheroid and many adhesion structures (Fig. 6B).
Role of pRp in hippo pathway. To corroborate the hypothesis that PRP inhibits CSCs proliferation and 
tumorigenesis through the Hippo pathway, we further determined the impact of PRP on YAP and P-YAP expres-
sion. We found that PRP treatment tended to decrease the expression of YAP on CSCs as judged by immuno-
fluorescence assay Fig. 6C. We then analyzed the expressions of YAP and p-YAP proteins by Western blotting. 
Analysis confirmed that PRP repressed YAP expression. Moreover, a negative correlation between YAP and 
p-YAP expression was found (Fig. 6D and Supplementary Fig. S6) with a marked increase in YAP phosphoryla-
tion induced by PRP treatment.
pRp inhibits tumour initiation and growth on nude mice. Here we show a xenograft study, with 
tumours generated from BxPC3 CSCs, to test the effect of PRP as a pre-treatment before tumour induction and 
as a pre-treatment and continuing treatment after tumour induction (Fig. 7A). 10 animals were used per group 
in agreement with others17. Nevertheless, one of the main difficulties of interpreting xenograft studies data is 
the loss of individuals, due to early death, that inevitably occurs during the time-period of the experiment18. 
In our study, 2 animals from the pre-treatment group and 4 animals from the pre-treatment + treatment group 
died before completing the experiment (due to anesthesia and ulceration issues). These sudden deaths were not 
related to an adverse effect of PRP, but rather due to technical problems with the compound administration. 
Results showed here have been normalized by the final “n” of each experimental group. We found that PRP 
treatment led to significant reduction in tumour development, thus 9 out of 10 control mice did present palpable 
tumours; on the contrary, only 3 out of 8 pre-treated mice and 3 out of 6 pre-treated + treated mice developed 
tumours (Fig. 7B,C). Therefore, tumour incidence (%) represented a 41% in the pre-treated mice and a 50% in the 
pre-treated + treatment group, indicating a clear suppressive effect of PRP on pancreatic CSC´s tumour engraft-
ing (Fig. 7D). Further, the evolution of tumour growth was evaluated measuring tumour volumes every 2 days for 
34 days (Fig. 7E), demonstrating that PRP treatment and the follow up treatment with PRP significantly inhibits 
tumour growth. Next, we examined the Tumourigenesis Index (TIn) that relates tumour incidence and tumour 
weight. This index can be used as a measure of malignancy or tumour aggressiveness. Figure 7F shows that sig-
nificant differences were appreciated in TIn when the mice were pre-treated and treated with PRP, indicating the 
anti-tumourigenesis effect of PRP. In conclusion, PRP impaired engrafting of pancreatic CSC’s tumours in nude 
mice and displayed an antigrowth effect toward initiated xenografts.
The histological analysis of BxPC-3 tumours sections showed differences in tumour characteristics, par-
ticularly in the amount of fibrotic tissue, when comparing tumours of the same size. Large necrotic areas were 
observed (nude areas) in treated tumours compared to untreated controls (Fig. 8A,B). Hematoxilin and eosin 
staining showed an increased labelling of stromal proteins in control tumour tissues when compared to tumour 
sections from the pre-treatment and pre-treatment + treatment groups (Fig. 8A). In adittion, Masson’s Trichrome 
staining showed that pancreatic CSCs induced tumours form large islets of cohesive cells embedded in an abun-
dant collagenous stroma (green) (Fig. 8B, CTL). Interestingly, the presence of extracellular matrix proteins fibers 
was strongly reduced in tumours isolated from mice that had been treated with PRP. The presence of abundant 
lacunae and unhealthy connective tissue can be seen within the fibrotic tissue area (Fig. 8B).
Moreover, the tumorigenic stem-like cell marker CD44 expression was analysed in tumour sections by immu-
nofluorescence assay. Control tumour sections exhibited a strongly positive CD44 labelling while tumour sections 
bellonging to the treatment groups displayed weak CD44 staining consistent with the antitumour effect produced 
by PRP treatment (Fig. 8C).
Discussion
Cancer stem cells (CSCs) have been characterized as immortal cells (due to their high telomerase activity) with 
a great tumour-initiating capacity. Furthermore, they can self-renew and they have unique properties, including 
pluripotent features, high metastatic potential, quiescent capacity and radio- and chemo-resistance1, thus strate-
gies to eradicate CSCs population are needed to prevent cancer recurrence.
Here we have tested the potential therapeutic effect of a pro-enzyme pancreatic preparation, PRP, on pancreatic 
enriched CSCs population, and shown that PRP treatment in vitro decreased the percentage of ALDH1-positive 
cells as well as the percentages of cells expressing the pancreatic CSC-specific biomarkers CD326, CD44 and 
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Figure 6. Representative confocal images of tumorigenic proteins in PRP treated pancreatic CSCs versus non-
treated CSCs. (A) Treatment with PRP maintain membrane-associated β-catenin without nuclear translocation 
in pancreatic CSCs. (B) PRP treatment increased membrane-associated E-cadherin. Cell surface β-catenin 
and E-cadherin expression was detected in red and nuclei were counterstained with DAPI (blue). Scale bar 
represents 20 μm. (C) PRP treatment decreased the protein expression of YAP in BxPC3 CSCs. YAP expression 
appears green and nuclei stained with DAPI (blue). Scale bar represents 10 μm. (D) Western blot analysis of 
YAP and p-YAP proteins in CSCs treated with PRP versus non-treated. A negative correlation between YAP and 
p-YAP expression was found.
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CXCR419. In addition, PRP treatment induced an inhibition of both primary and secondary sphere formation 
ability of treated pancreatic CSCs, in fact, tumour-derived spheroid structures have been reported to be related to 
an enrichment of the CSC subpopulation20.
Figure 7. PRP reduced tumour growth of pancreatic CSCs in vivo. (A) Scheme of the in vivo study design to 
determine antitumour activity of PRP against pancreatic CSCs induced tumours. Perpendicular bars stand 
for PRP bolus injection. BxPC3 CSCs injection into the flank of nude mice is represented by a red arrow. (B) 
Photographs of the subcutaneous tumors isolated from mice included in the control and PRP treated groups 
at the end of the experimental protocol. (C) Tumour weight of each single tumour (different colour circles) at 
Termination (mg), mice with no tumour are represented by a colour circle on the X axis. (D) Tumour incidence. 
Percentage of mice with tumours respect to control group which represented a 100% of tumour incidence. (E) 
Tumour size evolution over time. MEM ± SE. *p < 0.05 vs. control group. (F) Tumorigenesis Index (TIn). This 
index relates tumour incidence and tumour weight. Percentage of mice with tumours respect to control group 
which represented a 100% of tumour incidence. Mean Tin ± SE at Termination. Different letters stand for 
significant differences (p < 0.05).
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To determine the effect of PRP treatment at mRNA expression level we performed a series of microarray 
analysis and proved that a wide range of genes closely related to the CSCs phenotype, the EMT process, cell prolif-
eration, metastasis, cell adhesion, tumour suppression mechanisms, cytokine signalling and kinase activities were 
altered by the treatment. We found that OCT4 which has been reported to play a key role in the maintenance of a 
stem-like phenotype in pancreatic CSCs was down-regulated by PRP21. Moreover, it is important to highlight the 
down-regulation of DLK1, induced by PRP treatment, as this factor has been reported to play a significant role in 
the ability to form spheroid-like structures associated with the CSC phenotype22. These results correlate with the 
decrease in the CSCs population after PRP treatment shown above.
In addition, PRP treatment induced up-regulation of proven tumour suppressor genes such as the transcrip-
tion factor FOXP1, a tumour suppressor lost in several tumour types23. and TWIST2 and THY124,25.
Interestingly, the Notch signalling pathway, which is aberrantly activated in many types of malignancies and 
which is a key regulator of the EMT process26,27, was found to be inhibited by PRP. In fact, the expression of sev-
eral Notch initiating genes, including NOTCH1, JAG1, FGF and PDGFR was downregulated by PRP treatment. 
Furtheremore, EMT-related genes, such as Snai1 and Snai2 (also known as Slug) that are target genes of the Notch 
Figure 8. Effects of PRP on ECM deposition and pancreatic cancer marked CD44 expression. Representative 
images of tumour sections histologicaly staining with haematoxylin-eosin (H&E) (A) and Masson’s Trichrome 
(MS). (B) Tumours isolated from treated mice showed less fibrotic tissue (pink staining for the H&E test 
and green staining for the MS labellin) when compared with tumours isolated from control mice. (C) 
Immunofluorescence staining of pancreatic tumour sections with CD44 (red channel) demonstrated that 
tumours from non-treated mice had increased expression of CD44. Magnification, 10×.
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pathway were down-regulated by PRP treatment. In addition, E-cadherin, a gene suppressed by the Notch path-
way, was up-regulated after PRP treatment26.
In studying cytokine expression we found that interleukin-8 (IL-8), a pro-inflammatory factor, belonging 
to the CXC chemokine family was down-regulated by PRP. Cancer cells secrete IL-8 in an autocrine manner to 
achieve a proper tumour microenvironment28,29. Particularly, IL-8 and IL-8 receptors have been shown to be 
over-expressed in pancreatic cancer, but suppressed in normal pancreatic tissues, suggesting that IL-8 plays an 
important role in the invasiveness of human pancreatic cancer30. In addition, treatment with PRP dramatically 
decrease the expression of SPP1. This protein plays a crucial role in determining the metastatic potential of var-
ious cancers31, promotes cancer cell survival and regulates tumour-associated angiogenesis and inflammation32. 
Moreover, both JNK and ERK pathways were down-regulated as a consequence of PRP treatment, which is signif-
icant since those pathways are crucial in the control of cell proliferation and tumour malignancy. We observed a 
marked down-regulation of MEK1 (MAP2K1) a cue member of the ERK pathway. Remarkably, MEK inhibitors 
have been tested in clinical trials as anti-tumour agents, for instance PD0325901, a second generation MEK1/2 
inhibitor33. Therefore, PRP seems to control cell proliferation by inhibiting both JNK and ERK pathways through 
suppression of the expression of two relevant oncogenic transcription factors JUN and FOS.
Furthermore, PRP induced the up-regulation of cyclin-dependent kinase inhibitors genes (CDKN2A; 
CDKN2, 2 and CDKN2C) which are considered important tumour suppressor genes. Here we found that PRP 
significantly decreased the expression of DLK1 in treated pancreatic CSCs. Recent studies have shown that DLK1 
knockdown could suppress the ability of proliferation, colony formation, spheroid colony formation, and in vivo 
tumorigenicity of hepatic CSCs22. In addition, the SFN-1 (YWHAZ) gene was dramatically down regulated by 
PRP treatment. YWHAZ knockdown by specific siRNAs, has been shown to inhibit the proliferation, migration, 
and invasion of YWHAZ-overexpressing gastric cancer cells34. Feldmann and Maitra (2008)35 have reviewed 
the molecular genetics of pancreatic ductal adenocarcinomas and presented three important tumour suppressor 
genes that are deleted in a high percentage of pancreatic cancers: p16; SMAD4 and TP53. These genes inhibit cell 
proliferation by arresting cell cycle progression. Of interest, PRP up-regulates the expression of these same genes, 
suggesting the role of PRP in suppressing cell proliferation and malignant transformation.
Some studies state that the TGFβ signalling pathway can exert a tumour suppressive role in earlier stages 
of tumour development and change to a tumorigenic pathway in the advanced stages after losing Smad436, 
TGFβR237, TGFβR338 or RAC1b39 expression and gain overexpression of TGFβ139. Interestingly, our results reveal 
a down-regulation of TGFβ1 and an up-regulation of TGFβ2, TGFβ3, Smad4 and RAC1b in treated cells, suggest-
ing that PRP treatment promotes the TGFβ pathway role via a tumour suppressive route.
In the line of the changing nature of TGFβ pathway during tumour progression, it has been pointed that 
Smad7, a TGFβ pathway component, can be considered as a “swith” acting as an inhibitor of TGFβ pathway 
in early stages of tumour progression and as a enhancer of tumour invasion in late stages. Indeed, Smad7 has 
been shown to be overexpressed in many cancer types and its abundance can be positively correlated with the 
malignancy potential40. Here we shown a down-regulation of Smad7 in treated cells, supporting the idea that 
PRP treatment promotes a deep change in TGFβ pathway and decreases tumour malignancy. Additionally, PRP 
treatment up-regulated KLF17 expression, which enhances TGFβ/Smad-dependent signalling pathway direct-
ing cell differentiation41 and not toward cell stemness. Moreover, treated pancreatic CSCs exhibited a decreased 
activation of both Smad-dependent and Smad-independent branches of TGFβ pathway as shown by the reduc-
tion Smad2/3 phosphorylation, even under TGFβ stimulation, and the reduction of p38 phosphorylation. 
Interestingly, RAC1b has been described to act as a “retaining wall” of TGFβ pathway preventing the hyperacti-
vation of Smad-dependent and Smad-independent branches of TGFβ pathway42,43. Here we have shown that PRP 
up-regulate RAC1b which matches with the decreased phosphorylation of Smad2/3 and p38 found.
The expression of miR-21-5p, miR-182-3p and miR-7 was analysed after PRP treatment and was found that 
PRP treatment decreased the expression of miR-21-5p and miR-182-3p and up-regulated the expression of 
miR-7. FOS and JUN form the protein complex known as Activated Protein 1 (AP1) which plays a key role in 
cancer development44 and is up-regulated in the CSCs population promoting chemoresistance through miR-
21 enhancement in these cells45. Therefore, the down-regulation of FOS and JUN and the down-regulation of 
miR-21 suggests that PRP treatment may inhibit the activity of AP-1 complex and, subsequently, it may pro-
mote the chemo-sensitization of the treated pancreatic CSCs, which is in agreement with the disruption of the 
CSC phenotype discussed above. Furthermore, miR-21 has been described to suppress Smad4 expression cells46, 
thus the down-regulation of miR-21 after PRP treatment seems to be linked to the up-regulation of Smad4 and 
to the alteration of the TGFβ pathway found in treated cells. PRP treatment also diminished the expression of 
miR-182-3p, others have proposed that up-regulation of miR-182 correlates with the hyperactivation of TGFβ 
pathway47, therefore, the down-regulation of miR-182 in treated CSCs supports the hypothesis that PRP may 
be suppressing the hyperactivation of TGFβ pathway. Last, PRP treatment up-regulated the expression of miR-7 
which is considered a tumour suppressor since it has been found to suppress the EMT process and the stemness 
of CSCs in some tumours48,49.
Moreover, mRNA levels of MST1/2, SAV1 and LATS1/2 were found to be upregulated by PRP, together with 
an increased amount of phospho-YAP protein proved by western blotting. YAP and TAZ belong to the Hippo 
signalling pathway and are accumulated in the cytoplasm by phosphorylation prompted by MST1/2, SAV1 
and LATS1/2. Thus, phosphorylation secuestrates these proteins in the cytoplasm, preventing migration to the 
nucleus and the activation of downstream genes involved in cell proliferation50,51. Likewise, the inhibition of 
the activation (phosphorylation) of p38 shown here is relevant since p38 pathway has been described as block-
ing the phosphorylation of YAP, which correlates with the increment of phosphorylated YAP shown here after 
PRP treatment of pancreatic CSCs52. It appears that PRP treatment inhibits the uncontrolled proliferation pro-
moted by an aberrant hyperactivation (dephosphorylation) of YAP, which is a common event in many types of 
malignancies51,53,54.
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In addition, cytoplasmic phospho-YAP has been reported to promote the phosphorylation and the retention 
of β-catenin in the cytoplasm55, which correlates with our findings with immunofluorescent assays. β-catenin is a 
key component of the Wnt signalling pathway, which is over-activated causing a strong enhancement of cell pro-
liferation and tumour progression in many types of malignancies56. In the absence of Wnt-related ligands (Wnt1, 
Wnt2, Wnt3…), β-catenin is consistently phosphorylated and retained in the cytoplasm and, subsequently, it 
cannot migrate to the nucleus and activate pro-tumorigenic target genes57. According to these data along with 
the down-regulation of some Wnt-related initiating ligands such as WNT1 or WNT11 and the up-regulation of 
several Wnt pathway-suppressors including SOX1058 and SIRT159 shown here, we conclude that PRP treatment 
strongly inhibits the canonical WYT pathway56. Adittionaly, the increased phosphorylation of YAP after PRP 
treatment could also explain the inhibition of Notch pathway suggested above54.
Finally, we present a xenograft study to analyse the effect of PRP in vivo. Our results suggest that pre-treatment 
with PRP might inhibit the production and the action of growth factors and angiogenic stimulating factors that 
are necessary to prepare the tumour niche and, consequently, it reduces the possibility of tumour engrafting. In 
fact, the anti-angiogenic effect of PRP has been previously proven by our previous studies9. Interestingly, TGFβ-
1, an essential factor to create, maintain and support CSCs60 was strongly down-regulated after PRP treatment, 
which agrees with other studies that demonstrated oral therapy with proteolytic enzymes decreased TGFβ in 
human blood (Desser et al. 2001).
Moreover, our histological analysis of the xenografting mice models shows a decreased amount of 
tumour-surrounding fibrotic tissue of treated mice which can be explained by the strong down-regulation of 
TGFβ-1 by PRP treatment as TGFβ-1 has been described to be closely related to the corruption of healthy fibro-
blasts into cancer-associated fibroblasts (CAFs)61,62. Additionally, it has also been reported that the surrounding 
tumour microenverioment also promotes the appearance of new CSCs derived from non-stem cancerous cells 
by secreting several factors such as IL6, HGF or TGFβ-163. Consequently, pre-treatment and follow up treatment 
with PRP might decrease TGFβ-1 and, subsequently, it might impair CSCs tumour engrafting, niche formation 
and even CSCs subpopulation activation. Further, treated tumours showed a decreased expression of the pan-
creatic cancer marker CD44. Knockdown of CD44 expression in pancreatic cancer cells has been linked with 
decreased cellular proliferation, invasiveness and increased sensitivity to gemcitabine64.
In summary, the present study demonstrates the high anti-tumour efficacy of PRP against human pancreatic 
CSCs, both in vitro and in vivo. The molecular PRP findings presented demonstrates that PRP treatment pro-
motes the up-regulation of RAC1b which avoids the hyper-activation of the p38 pathway induced by the TGFβ 
pathway leading to the phosphorylation of YAP observed in our results, which also explains the blockage of the 
canonical Wnt pathway, the inhibition of the Notch pathway as well as the cytoplasmic location of β-catenin in 
treated cells as discussed above. Morover, the regulation of TGFβ, Hippo, Wnt and Notch pathways could explain 
the disruption of the CSC phenotype and the EMT process found in treated cells. Finally, we reported that PRP 
impaired engrafting of pancreatic CSC’s tumors in nude mice and displayed an antigrowth effect toward initiated 
xenografts, making (pro)enzymes treatment a valuable strategy to reduce CSC population for pancreatic cancer 
therapy. As cancer treatment moves towards more personalised medicine, proper therapies to target and treat 
specifically CSCs may prove to be a useful method for reducing recurrence after drug treatment failures.
Material and Methods
pancreatic pro-enzymes. The pancreatic pro-enzymes Chymotrypsinogen A and Trypsinogen were sup-
plied by AplyChem. A stock solution of 6 mg/ml of Chymotrypsinogen A and 1 mg/ml of Trypsinogen was made 
dissolving the pancreatic enzymes in PBS and stored at −20 °C. For each experiment, the stock solution was 
further diluted in a medium to obtain the desired concentrations.
cell line. The human pancreatic cancer cell lines BxPC3 was obtained from American Type Culture Collection 
(ATCC) and maintained in RPMI 1640 Medium (Sigma-Aldrich) supplemented with 10% FBS. Cell disassocia-
tion for cell passing was done with the trypsin replacement TrypLE reagent (Life Technologies).
isolation of cScs. Cancer stem-like cells from BxPC3 pancreatic cancer (adenocarcinoma) cell line were 
isolated using the ALDEFLUOR assay (StemCell Technologies) by fluorescence-activated cell sorting (FACS) and 
enriched subpopulation of CSCs were grown with our specific sphere forming medium (PCT/ES2015/070606, 
Jiménez et al. 2018) in ultralow attachment plates (Corning).
Mtt cell proliferation assay. The effect of PRP on cell viability and proliferation was assessed using the 
MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) assay (Sigma-Aldrich). Briefly, cells 
(2 × 103 cells/well) were seeded onto 96- well plates and incubated for 24 h and then treated with different PRP 
concentrations (Fig. 1A). Three days later, treatment was repeated and cells were maintained for 3 additional 
days. Cells were maintained with the drug for six days. Thereafter, cells were processed as follows, 10 μL of 2 mM 
MTT reagent was added to each well and cells were incubated at 37 °C for 4 hours. 100 μL detergent reagent was 
then added and cells were left at room temperature in the dark for 2 hours. Absorbance was recorded at 570 nm. 
The IC50 values were calculated from four parametric logistic curves by linear interpolation using Sigma Plot 
software. All of the experiments were plated in triplicate wells and were carried out at least twice.
ALDEFLUOR assay and CSCs markers analysis by flow cytometry. Cancer stem-like cells from 
BxPC3 cancer cell line were labelled using the ALDEFLUOR assay kit according to the manufacturer’s recom-
mendations (StemCell Technologies). The enriched subpopulation of CSCs was characterized using a FACSAria 
III flow cytometer (Becton Dickinson).
To analyse CSC markers treated and not treated BxPC3 CSCs were disaggregated by tryple and washed twice 
in PBS supplemented with 1% bovine serum albumin (Sigma-Aldrich). The cell surface Fc receptor was blocked 
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using IgG (Santa Cruz Biotechnology) on ice for 15 min. Cells were stained for 30 min at 4 °C with anti-CD44-PE 
and anti-CD326 FITC and CxCR4-APC monoclonal antibodies (BD Biosciences). After washing, cells were ana-
lyzed using a FACSAria III flow cytometer (Becton Dickinson).
Effects of PRP and gemcitabine on BXPC-3 CSCs proliferation. Enriched subpopulations of CSCs 
from formed primary and secondary spheres were seeded in a concentration of 3000 cells/well in 96-well plates in 
sphere forming medium and treated with PRP (T/C 0.07/0.42 mg/mL), gemcitabine at 0,01 μm and with both PRP 
(T/C 0.07/0.42 mg/mL) and gemcitabine 0,01 μm. After 72 h, 0.01 ml of Cell Counting Kit-8 (CCK-8) (Dojindo 
Molecular Technologies), was added to each well and incubated at 37 °C for 2 h. Plates were read at 450 nm on a 
Bio-Rad plate reader.
PCR microarray analysis of human EMT, CSCs and MAP kinase signalling pathway related 
genes. BxPC3 enriched CSCs were grown in 6 well plates and treated twice with PRP (T/C 0.07/0.42 mg/mL) 
on day 2 and on day 4 or non-treated control cells (CTL). On day 5, total cellular RNA was isolated using TRIzol 
reagent (Life Technologies). A pool of three total RNAs extracted from three independent experiments was 
used for first strand cDNA synthesis using the kit SuperScript IV First-Strand Synthesis System (ThermoFisher 
Scientific).
PRP induced changes in expression of genes involved in the EMT process, related to CSCs or involved in 
MAP Kianse Signalling Pathway were analysed with RT2 Profiler PCR Arrays Human Epithelial to Mesenchymal 
Transition (PAHS-090Z, SABiosciences); RT2 Profiler PCR Arrays Human Cancer Stem cells (PAHS-
176Z, SABiosciences) or RT2 Profiler PCR Arrays Human MAP Kinane Signalling Pathway (PAHS-176Z, 
SABiosciences) respectively, and processed following the manufacturer’s instructions applied on the ViiA7 fast 
real-time PCR system (Applied Biosystemsen). A set of controls present on each array enabled data analysis using 
the ΔΔCT method of relative quantification and assessment of reverse transcription performance, genomic DNA 
contamination, and PCR performance.
Data analyses were performed using the web-based analysis software (http://pcrdataanalysis.sabiosciences.
com/pcr/arrayanalysis.php).
In vivo anti-tumour xenograft studies. To establish xenograft tumours six- to eight-week-old NSG 
immunodeficient mice were used. All procedures were approved and performed in accordance with the guide-
lines of the Institutional Animal Care and the Research Ethics Committee of the University of Granada. Mice 
were housed and maintained at 20 °C to 24 °C, 50% RH, a 14 to 10 h lightdark cycle with food and water ad 
libitum.
Animals (n = 10 per group) were randomly assigned as control, pre-treatment group and pre-treatment + treat-
ment group. Treated groups received Trypsinogen and Chymotrypsinogen A at a dose of 83.3/500 mg/kg in com-
bination in a single injection administered 3 days per week via intravenous tail vein injection in a dosing volume 
of 10 mL/kg. The volume of dosing solution administered to each animal was calculated and adjusted based on 
individual body weight measured immediately prior to dosing. Treatments were administered for 3 weeks before 
tumour induction (pre-treatment group) and for 3 weeks before tumour induction and continued during 9,5 
weeks after tumour induction (pre-treatment + treatment group); control group was inoculated with a physio-
logical saline solution (Fig. 7A).
Tumours were generated by subcutaneous injections of BxPC3 CSCs, to do so, CSCs spheres were disaggre-
gated and 500 viable cells were injected per mouse using 26-gauge needles. Tumour size was calculated according 
to the formula:
tumour volume (mm ) d D/2,3 2= ×
where d and D are the shortest and longest diameters, respectively. Paraffin-embedded blocks of all tumours 
were sectioned at 5 μm. Each sample was stained with hematoxylin and eosin (H&E) and Mason tricrome for 
histopathologic analysis. For CD44 staining tumour sections were labelled with HCAM (DF1485) (sc-7297, 
Sigma-Aldrich), at 4 °C overnight. Following washing with PBS, tumour sections were subsequently incubated 
with fluorescence conjugated secondary antibody for 2 h at RT. The sections were then mounted with mounting 
medium containing DAPI (Vector Laboratories). For negative controls, primary antibodies were replaced with 
PBS. Images were captured using a confocal fluorescence microscope (Leica DM 5500B microscope).
Quantitative real time Rt-pcR. ALDEFLUOR sorted BxPC3 pancreatic cancer cells were maintained for 
6 days in culture and treated twice (day 2 and day 5) with PRP - Chymotrypsinogen: 0.42 mg/ml - Trypsinogen: 
0.07 mg/ml. Total RNA was extracted using the TRIZOL reagent following the instructions of the manufacturer 
(Life Technologies). cDNA was synthesized by reverse transcription of total RNA using the Reverse Transcription 
System (Promega) and qRT-PCR assay was done using SYBR Green PCR Master Mix (Promega) and random 
primers. Each reaction was performed in triplicate from two cDNA dilutions. The comparative threshold cycle 
(Ct) method was used to calculate the amplification factor as specified by the manufacturer. Human GADPH 
was used as an internal standard to normalize variations in RNA quality in the quantities of input cDNA. The 
following primers were used for detection of Rac1 + Rac1b: 5′-ACCATGCAGGCCATCAAGTGTGTGG-3′ and 
5′-TTACAACAGCAGGCATTTTCTCTTC-3′. Measurement of Rac1b was performed with exon 3b-specific 
primers: 5′-GGAGAAACGTACGGTAAGGATATAACC-3′ and 5′-GGCAATCGGCTTGTCTTTGCCC-3′. 
Smad7 primer was obtained from Sigma. Primer sequences used for GAPDH was: 5′-TGCACCACCAACTGC 
TTAGC-3′ 5′-GGCATGGACTGTGGTCATGAG-3′.
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miRNA real-time reverse transcriptase PCR. To determine the expression of miRNAs (miR-21, miR-
182, miRNA-7 and miR-SNORD 44) (Exiqon) in control non-treated cells/PRP treated cells, TRIZOL Reagent 
(Life Technologies) was used according to the manufacturer’s recommendations. Reverse transcription from 
miRs was performed using the miRCURY LNATM Synthesis kit II (Exiqon) following the manufacturer’s proto-
col. qPCR was performed using miRCURY LNA TM EXILENT SYBR Green (Exiqon) in a CFX96 real-time PCR 
detection system (Bio-Rad). Each reaction was performed in triplicate and the comparative threshold cycle (Ct) 
method was used to calculate the amplification factor. Human Snord 44 was used as housekeeping.
tGfβ stimulation. BxPC3 enriched CSCs were grown in 6 well plates and treated twice with PRP (T/C 
0.07/0.42 mg/mL) on day 2 and on day 4 or non-treated control cells (CTL). On day 5, Recombinant Human 
TGF-beta 1 Protein (R & D Systems) was added to the cells in a concentration of 5 ng/ml, after 2, 4 and 10 hours 
of TGFβ stimulation cells were collected and processed for western blotting analysis.
Western blotting. Whole cell lysates were obtained through RIPA lysis buffer (Santa Cruz Biotechnology). 
The cytosolic and nuclear proteins were extracted with the use of a nuclear protein extraction kit (Beyotime 
Biotechnology). Protein concentrations were then determined using Bio Rad detergent compatible protein 
assays (Bio Rad Laboratories). Equal amounts of protein were loaded onto on SDS–PAGE gel, transferred onto 
nitrocellulose membranes (Bio Rad,162- 0115), and blocked in PBS containing 5% non-fat dry milk for 1 h at 
room temperature. Primary antibodies used included HCAM (DF1485) (sc-7297, Sigma-Aldrich), CXCR-4 
(4G10) (sc-53534, Santa Cruz), Ep-CAM (CD326) (EBA-1) (sc-66020, Santa Cruz), Phospho-Smad2/3 (pThr8, 
MERCK), Smad2/3 Antibody (07–408, MERCK), Phospho-p38 MAPK ((Thr180/Tyr182), D3F9), (#4511, 
Cell SignalingTechnology), p38 MAPK Antibody (#9212, Cell SignalingTechnology), GAPDH (#2118, Cell 
SignalingTechnology), Anti-Yap1(phosphoS127) antibody (ab76252, Abcam), Anti-YAP1 antibody [EP1674Y] 
(ab52771, Abcam) and β-ACTIN (A2228, Sigma-Aldrich) Secondary antibodies used included anti-rabbit IgG 
peroxidase conjugate (A0545, Sigma-Aldrich) and anti-mouse IgG peroxidase conjugate (A9044, Sigma-Aldrich). 
Protein–antibody complexes were visualized by enhanced chemiluminescence (ECL, Bonus) on a LAS 3000 
Imaging System (Fujifilm). Protein band Intensities were quantitated using Image-J software (NIH).
Immunofluorescence analysis. Cells were fixed with 4% paraformaldehyde in PBS for 20 min at room 
temperature (RT), blocked for 1 h at room temperature with 5% BSA, 5% FBS in PBS and incubated with the 
primary antibody overnight at 4 °C. Primary antibodies used were: HCAM (DF1485) (sc-7297, Sigma-Aldrich), 
CXCR-4 (4G10) (sc-53534, Santa Cruz), Ep-CAM (CD326) (EBA-1) (sc-66020, Santa Cruz), β-catenin (E-5) (SC-
7963, Santa Cruz), E-cadherin (67A4) (SC-21791, Santa Cruz), Sox-2 (H-65) (sc-20088, Santa Cruz) Anti-YAP1 
antibody [EP1674Y] (ab52771, Abcam) or p-Smad2/3 (SC11769, Santa Cruz).The next day, samples were washed 
three times with PBS, incubated with the secondary antibodies (Alexa) for 1 h at RT, washed three times with PBS 
and mounted with 4′,6-diamidino-2-phenylindole (DAPI)-containing mounting medium. Images were acquired 
with a Leica DM 5500B microscope.
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